Neurocrine Biosciences Inc vs Energy Select Sector SPDR Fund — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Energy Select Sector SPDR Fund trades at $58.47. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, Energy Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| NBIX | XLE | |
|---|---|---|
Market Cap | $17.40B | — |
Sector | Health | — |
52-Week High | $180.55 | $62.57 |
52-Week Low | $123.10 | $42.12 |
Enterprise Value | $16.49B | — |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →